Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometrySON, Junghyun; LEE, Jaeick; LEE, Mijin et al.Journal of pharmaceutical and biomedical analysis. 2004, Vol 36, Num 3, pp 657-661, issn 0731-7085, 5 p.Article

Oxiracetam pre- but not post-treatment prevented social recognition deficits produced with trimethyltin in ratsHLINAK, Zdenek; KREJCI, Ivan.Behavioural brain research. 2005, Vol 161, Num 2, pp 213-219, issn 0166-4328, 7 p.Article

Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in miceHLINAK, Z; VINSOVA, J; KASAFIREK, E et al.European journal of pharmacology. 1996, Vol 314, Num 1-2, pp 1-7, issn 0014-2999Article

Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometrySON, Junghyun; LEE, Jaeick; LEE, Mijin et al.Journal of pharmaceutical and biomedical analysis. 2004, Vol 36, Num 1, pp 183-187, issn 0731-7085, 5 p.Article

Oxiracetam prevented the scopolamine but not the diazepam induced memory deficits in miceHLINAK, Zdenek; KREJCI, Ivan.Behavioural brain research. 2002, Vol 133, Num 2, pp 395-399, issn 0166-4328Article

Determination of oxiracetam in human serum and urine by high-performance liquid chromatographyVISCONTI, M; SPALLUTO, R; CROLLA, T et al.Journal of chromatography. 1987, Vol 416, Num 2, pp 433-438, issn 0021-9673Article

Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteersPERUCCA, E; ALBRICI, A; GATTI, G et al.European journal of drug metabolism and pharmacokinetics. 1984, Vol 9, Num 3, pp 267-274, issn 0378-7966Article

Pre- and postprandial pyridostigmine and oxiracetam effects on growth hormone secretion in anorexia nervosaMANCINI, A; VALLE, D; CONTE, G et al.Psychoneuroendocrinology. 1996, Vol 21, Num 7, pp 621-629, issn 0306-4530Article

Direct chromatographic separation of the enantiomers of oxiracetamCAMILLERI, P; MURPHY, J. A; THORPE, C et al.Journal of chromatography. 1990, Vol 508, Num 1, pp 208-211, issn 0021-9673, 4 p.Article

Papers/Drugs affective cognitive disorders: a symposium. A session of the Collegium Internationale Neuro-Psychopharmacologicum. 14th meeting, Florence June 23, 1984Clinical neuropharmacology. 1986, Vol 9, issn 0362-5664, 84 p., suppl. 3Conference Proceedings

HPLC determination of oxiracetam, its impurities, and piracetam in pharmaceutical formulationsGAGLIARDI, L; DE ORSI, D; CAVAZZUTTI, G et al.Analytical letters. 1994, Vol 27, Num 5, pp 879-885, issn 0003-2719Article

Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsyALDENKAMP, A. P; VAN WIERINGEN, A; ALPHERTS, W. C. J et al.Neuropsychobiology. 1990, Vol 24, Num 2, pp 90-101, issn 0302-282XArticle

Avoidance facilitation in adult mice by prenatal administration of the drug oxiracetamAMMASSARI-TEULE, M; D'AMATO, F. R; SANSONE, M et al.Pharmacological research communications. 1986, Vol 18, Num 12, pp 1169-1176, issn 0031-6989Article

Facilitating effect of oxiracetam and piracetam on acquisition of discrete two-way shuttle avoidance in normal miceKURIBARA, H; TADOKORO, S.Japanese journal of pharmacology. 1988, Vol 48, Num 4, pp 494-498, issn 0021-5198Article

Effects of oxiracetam on electroencephalogram at rest in healthy young subjects: single- and repeated-dose investigationGUAZZELLI, M; ROCCA, R; LATTANZI, L et al.Current therapeutic research. 1987, Vol 41, Num 2, pp 234-243, issn 0011-393XArticle

Improvement of avoidance acquisition by the nootropic drug oxiracetam in miceSANSONE, M; CASTELLANO, E; AMMASSARI-TEULE, M et al.Archives internationales de pharmacodynamie et de thérapie. 1985, Vol 275, Num 1, pp 86-92, issn 0003-9780Article

Effects of acute doses of oxiracetam in the scopolamine model of human amnesiaPREDA, L; ALBERONI, M; BRESSI, S et al.Psychopharmacologia. 1993, Vol 110, Num 4, pp 421-426, issn 0033-3158Article

Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjectsLECAILLON, J. B; DUBOIS, J. P; COPPENS, H et al.European journal of drug metabolism and pharmacokinetics. 1990, Vol 15, Num 3, pp 223-230, issn 0378-7966, 8 p.Article

The effects of oxiracetam and D-amphetamine on all-night electroencephalogram sleep in young healthy subjectsMAGGINI, C; GUAZELLI, M; CIAPPARELLI, A et al.Current therapeutic research. 1988, Vol 43, Num 5, pp 979-990, issn 0011-393XArticle

Oxiracetam pharmacokinetics following single and multiple dose administration in the elderlyPERUCCA, E; PARINI, J; ALBRICI, A et al.European journal of drug metabolism and pharmacokinetics. 1987, Vol 12, Num 12, pp 145-148, issn 0378-7966Article

Solid-state structure and conformation of the nootropic agent 4-hydroxy-2-oxo-1-pyrrolidineacetamide: X-ray and theoretical self-consistant field molecular orbital (SCF-MO) studiesBANDOLI, G; GRASSI, A; NICOLINI, M et al.Chemical and pharmaceutical bulletin. 1985, Vol 33, Num 10, pp 4395-4401, issn 0009-2363Article

Determination of oxiracetam in plasma and urine by column-switching high-performance liquid chromatographyLECAILLON, J. B; SOUPPART, C; LE DUIGOU, F et al.Journal of chromatography. 1989, Vol 497, pp 223-230, issn 0021-9673Article

Effect of oxiracetam on cerebral cholinergic imbalance secondary to an NMDA-receptor blockadePONZIO, F; BELFIORE, P; DORIGOTTI, L et al.Pharmacological research. 1989, Vol 21, pp 103-104, issn 1043-6618, suppl. 1Conference Paper

Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementiaVILLARDITA, C; PARINI, J; GRIOLI, S et al.Journal of neural transmission. Supplementum. 1987, Num 24, pp 293-298, issn 0303-6995Conference Paper

Controlled clinical trial of oxiracetam in the treatment of chronic cerebrovascular insufficiency in the elderlyFERRERO, E.Current therapeutic research. 1984, Vol 36, Num 2, pp 298-308, issn 0011-393XArticle